New S-Elixhauser comorbidity score may not be more advantageous for predicting in-hospital and long-term mortality

hospital records

A cohort study from Johns Hopkins Bloomberg School of Public Health has found that the newly developed summary Elixhauser (S-Elixhauser) comorbidity score is well calibrated and internally validated to predict in-hospital, 30-day, and 1-year mortality but its advantage over the existing Agency for Healthcare Research and Quality (AHRQ) Elixhauser and Charlson summary scores is unclear. The report is published in Annals of Internal Medicine.

Summary comorbidity scores, such as the Charlson comorbidity index and the Elixhauser comorbidity index, can both describe comorbidity burden in observational studies and be used for prognosis. The set of Elixhauser comorbidity indicators was developed in 1998 but has undergone modifications, including the addition of weighted scores and expanded comorbidity codes. AHRQ also derived and evaluated the model fit of a summary Elixhauser score, based on weighting the individual comorbidities, to predict in-hospital mortality and 30-day all-cause re-admissions in hospitalized adults. However, the performance of the summary score has not previously been evaluated for predicting longer-term mortality outcomes, nor has it been validated for use in older adults.

Source: Read Full Article